Luteal phase defects following agonist-triggered ovulation: a patient-dependent response

Emperaire, J C; Parneix, I; Ruffie, A

doi:10.1016/s1472-6483(10)62105-0

Cited by 37 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar clinical outcome was observed with 0.1 mg of triptorelin and 10,000 IU hCG in a GnRH antagonist protocol in a study that was presented during the 19 th ESHRE meeting but has not yet been published (19). In a recent study of oocyte maturation using 0.1, 0.3, and 0.5 mg triptorelin, ovulation occurred in all IUI cycles (17).…”

Section: Discussionmentioning

confidence: 94%

“…Although there are many reports about the optimal dose of hCG for inducing final oocyte maturation, there are limited data about the minimal optimal doses to trigger using GnRH agonists in IVF cycles (6,7,17,18). Most previous studies have reported successful oocyte maturation with 0.2-0.3 mg triptorelin, 0.5 mg buserelin, and 1 mg leuprolide acetate (13).…”

Section: Discussionmentioning

confidence: 99%

“…Fertilization rates were similar in both groups (72% in group 1 and 73% in group 2). The nean number of embryos was 10.11±5.86 (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) in group 1 and 10.79±3.14 (7-18) in group 2. The numbers of transferred embryos were 1.85±0.37 (1-2) and 1.36±0.49 (1-2) in groups 1 and 2, respectively (p<0.05).…”

Section: A Cycle Characteristics Of Group 1 Including Fresh and Thamentioning

confidence: 97%

See 2 more Smart Citations

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Gülekli¹,

Göde²,

Sertkaya³

et al. 2015

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Objective:To investigate the efficacy of low-dose gonadotropin-releasing hormone (GnRH) agonist for final oocyte maturation in females undergoing assisted reproductive treatment (ART) cycles. Material and Methods:Nine females undergoing ovarian stimulation in a GnRH antagonist protocol who received triptorelin 0.1 mg to trigger final oocyte maturation were included. Treatment outcomes of these patients were compared with those of controls, matched for age and oocyte number (n=14), who received 0.2 mg triptorelin at the same time. The luteal phase was supported with vaginal micronized progesterone and oral estradiol hemihydrate 2 mg twice daily. Results:The mean (±) numbers of retrieved, metaphase II, and fertilized oocytes were 15.66±7.82, 14±7.28, and 10.11±5.86, respectively.The implantation and clinical pregnancy rates were 46.1% and 71.4%, respectively. Of the pregnancies, 2 were live births, 1 was a preterm birth (twins), 2 are on-going, and 2 ended as miscarriages. No case of OHSS was encountered. On comparison of the results of these patients (fresh cycles; n=7) with those of matched controls, there were no significant differences in terms of retrieved mature oocytes, implantation rates, or clinical pregnancy rates (p>0.05). Conclusion:These findings suggest that low-dose GnRH agonist triggering has similar efficacy as standard doses in terms of retrieved mature oocytes and clinical pregnancy rates in in vitro fertilization cycles. (J Turk Ger Gynecol Assoc 2015; 16: 35-40) Keywords: Agonist trigger, triptorelin, oocyte maturation, oocyte retrieval, pregnancy rate Received: 21 June, 2014 Accepted: 05 December, 2014 Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series AbstractOriginal Investigation

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: A Cycle Characteristics Of Group 1 Including Fresh and Thamentioning

confidence: 97%

See 1 more Smart Citation

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Gülekli¹,

Göde²,

Sertkaya³

et al. 2015

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

show abstract

“…Another point of caution is that while triggering with GnRH seems to avoid early hyperstimulation, this approach has only a minimal ability to prevent a late hyperstimulation following the appearance of hCG from an implanting embryo. Furthermore, the main drawback of triggering ovulation with a GnRH agonist is the tendency to produce a shortened or inadequate luteal phase in about one-third of the cycles, at least in some patients [ 28 ]. This insuffi ciency may be secondary to the shorter duration of the induced gonadotropin surge in comparison with the normal physiologic pre-ovulatory peak, or it may be caused by a temporary refractoriness of pituitary gonadotrophs and/or the luteal gland.…”

Section: Therapeutic Triggering Of Ovulationmentioning

confidence: 99%

Triggering Ovulation

Emperaire¹

2015

Ovulation Stimulation With Gonadotropins

View full text Add to dashboard Cite

“…Suboptimal results have been described after GnRH bolus, due to a deficient LH surge (Castillo et al, 2012). Numerous dosage protocols have been proposed to trigger follicular maturation; from as low as 0.1mg to as high as 0.4mg, without having clear evidence of neither one's benefit (Buckett et al, 1998;Emperaire et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Comparison of two different dosage of GnRH agonist as ovulation trigger in oocyte donors: a randomized controled trial

Zarcos

Mejia

Stefani

et al. 2017

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective: To compare the results obtained with two different GnRH agonist dosages: 0.3mg versus 0.4mg to trigger ovulation in oocyte donor cycles.Methods: Experimental controlled randomized trial including 40 patients from a private practice center. The patients were randomized into two groups. Group A received a single dose of Triptorelin 0.3mg (Decapeptyl ® ) 36 hours before pick-up. Group B patients received Triptorelin 0.4mg (Decapeptyl ® ) before pick-up to final oocyte maturation. We evaluated the total number of oocytes collected, the number of mature oocytes and total days of ovarian stimulation.Results: The average of total collected oocytes were 16 (Group A) versus 15 (Group B), and the mean number of mature oocytes were 13 versus 12 respectively. The only variable showing a difference was the percentage of mature oocytes, which was greater in Group A, resulting in 84.6%, in contrast with those treated with 0.4mg of Triptorelin (78.6%), although these differences were not statistical significant (p=0.35). Days of stimulation did not differ between groups. No cases of empty follicle syndrome were reported.Conclusions: We found that an increase from 0.3 to 0.4mg of triptorelin in an oocyte donation program might not improve outcomes. Nevertheless, more studies might be necessary, not only in oocyte donors but in sterile women as well, to evaluate how GnRH agonist dosage could affect the results among other factors.

show abstract

Luteal phase defects following agonist-triggered ovulation: a patient-dependent response

Cited by 37 publications

References 35 publications

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Triggering Ovulation

Comparison of two different dosage of GnRH agonist as ovulation trigger in oocyte donors: a randomized controled trial

Contact Info

Product

Resources

About